Utilización de Upadacitinib en el tratamiento de la enfermedad de Crohn: reporte de dos casos clínicos

Simple item page
dc.creatorQuera, Rodrigo
dc.creatorCórdova, Andrea
dc.creatorNúñez, Paulina
dc.creatorCorrea, Ismael
dc.creatorFlores, Lilian
dc.date2024
dc.date.accessioned2025-11-18T19:50:05Z
dc.date.available2025-11-18T19:50:05Z
dc.description<p>Crohn's disease (CD) is a chronic, progressive inflammatory disease with complications that impact the well-being of patients. The therapeutic advances achieved in recent decades, especially through the advent of biological therapy, have allowed for a transformation in the approach and management of CD, thereby modifying the course of this disease. However, a significant number of patients do not experience a satisfactory response to these drugs or lose it during the course of the disease. In this scenario, a viable alternative is to switch medications. Upadacitinib, a novel Janus kinase inhibitor, has emerged as a promising strategy for the management of CD. We presented two cases of patients with CD refractory to conventional therapy and biological therapy, who responded successfully to treatment with upadacitinib.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/26c83b63-aee0-4769-b4bc-73921cef387f
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/56430
dc.languagespa
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.44 (2024) date: 2024-04-01 nr.2 p.162-166
dc.titleUtilización de Upadacitinib en el tratamiento de la enfermedad de Crohn: reporte de dos casos clínicosspa
dc.titleUtilization of Upadacitinib in the treatment of Crohn's disease: a report on two clinical caseseng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE